Kailera Therapeutics, Inc. (KLRA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $1.68B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.79M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $15.98M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-532.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $11.98M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $229.00K.
- 2025-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m).
Kailera Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | $1.68B | $-1.79M | $-558.84M | $1.12B | 3 month · $8.34M |
| 2026-03-31 | (m) | $0.00 | $15.98M | $-532.00K | $-447.53M | $-432.09M | 3 month · $3.94M |
| 2025-12-31 | $0.00 | $0.00 | $11.98M | $229.00K | $-368.67M | $-356.46M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $-262.58M | 3 month · $1.63M |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | $-235.24M | 3 month · $1.52M |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $-218.77M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |